Omnicell, Inc. is a provider of medication management solutions and adherence tools for health systems and pharmacies. The Company is focused on transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care through a portfolio of robotics, smart devices, intelligent software, and services. Its point of care automation solutions is designed to improve clinician workflows in patient care areas of the healthcare system, such as nursing units, patient wards, operating rooms, and emergency departments. The Companyâs XT Series automated dispensing systems for medications and supplies, which are used in nursing units and other clinical areas of the hospital, are designed to support workflows specific to each area of the hospital, with various software and hardware options. For the operating room, the Company also offer specialized automated dispensing systems.

Employees

3,600

Sector

Advanced Medical Equipment & Technology

Calendar

02-04 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
25-12-09	43.67 $	+0.28%	598,994
25-12-08	43.55 $	+7.54%	1,297,840
25-12-05	40.50 $	+2.23%	440,274
25-12-04	39.61 $	-2.15%	566,395
25-12-03	40.48 $	+5.25%	634,687

Delayed Quote Nasdaq, December 09, 2025 at 02:24 pm

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

43.55USD

Average target price

48.17USD

Spread / Average Target

+10.60%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Real-time Estimate Cboe BZX Other stock markets 14:39:44 2025-12-09 EST			5-day change	1st Jan Change
43.71 ^USD	+0.37%		+13.55%	-1.91%

09:20pm	Omnicell, Inc. - Special Call
12-08	Omicell, Inc. Announces the Launch of Omnicell Titan XT	CI

Capitalization	1.95B 1.68B 1.58B 1.47B 2.7B 176B 2.94B 18.27B 7.1B 83.23B 7.33B 7.18B 307B	P/E ratio 2025 *	148x	P/E ratio 2026 *	74.4x
Enterprise value	1.95B 1.68B 1.58B 1.47B 2.7B 176B 2.94B 18.27B 7.1B 83.23B 7.33B 7.18B 307B	EV / Sales 2025 *	1.65x	EV / Sales 2026 *	1.59x
Free-Float	80.46%	Yield 2025 *	-	Yield 2026 *	-

09:20pm	Omnicell, Inc. - Special Call
12-08	Omicell, Inc. Announces the Launch of Omnicell Titan XT	CI
11-13	Evoke Pharma Q3 sales rise 61%, expects QOL Medical acquisition to close in Q4 2025	RE
10-30	Tranche Update on Omnicell, Inc.'s Equity Buyback Plan announced on May 22, 2025.	CI
10-30	Omnicell Q3 Non-GAAP Net Income Declines, Revenue Rises; 2025 Revenue and EPS Guidance Raised	MT
10-30	Omnicell, Inc., Q3 2025 Earnings Call, Oct 30, 2025
10-30	Omnicell, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
10-30	Omnicell, Inc. Updates Earnings Guidance for the Full Year 2025	CI
10-30	Omnicell, Inc. Provides Earnings Guidance for the Fourth Quarter 2025	CI
10-30	Omnicell Q3 adjusted EPS beats estimates, driven by connected devices and services	RE
10-30	Earnings Flash (OMCL) Omnicell, Inc. Posts Q3 Adjusted EPS $0.51 per Share, vs. FactSet Est of $0.36	MT
10-30	Earnings Flash (OMCL) Omnicell, Inc. Reports Q3 Revenue $310.6M, vs. FactSet Est of $295.6M	MT
10-30	(OMCL) Omnicell, Inc. Expects Q4 Adjusted EPS Range $0.40 - $0.50	MT

05-23	Piper Sandler Adjusts Omnicell Price Target to $57 From $46, Maintains Overweight Rating	MT
05-14	Wells Fargo Upgrades Omnicell to Overweight From Equal Weight, Adjusts Price Target to $35 From $31	MT
01-06	BofA Securities Adjusts Price Target on Omnicell to $46 From $54	MT
24-10-31	BofA Securities Downgrades Omnicell to Neutral From Buy, Adjusts Price Target to $57 From $44	MT
24-08-02	Barclays Upgrades Omnicell to Equalweight From Underweight, Adjusts Price Target to $39 From $26	MT

Omnicell, Inc. Stock

Equities

OMCL

US68213N1090

Advanced Medical Equipment & Technology

Valuation: Omnicell, Inc.

Chart: Omnicell, Inc.

Latest news: Omnicell, Inc.

Last Transcript: Omnicell, Inc.

Analysts' recommendations: Omnicell, Inc.

Press Releases: Omnicell, Inc.

News in other languages: Omnicell, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Omnicell, Inc.

ETFs: Omnicell, Inc.

Medical Software & Technology Services

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

12-08	Announcing Omnicell Titan XT, the Next Generation, Automated Dispensing System Designed to Empower Autonomous Medication Management	BU
12-01	Omnicell to Host Innovation Update and Q&A Session at Upcoming ASHP Midyear Industry Trade Show	BU
11-20	Omnicell to Present at the Piper Sandler 37th Annual Healthcare Conference	BU
11-13	Omnicell Achieves URAC Certification, Strengthening Compliance and Scalability for Health System-Owned Specialty Pharmacies	BU
10-30	Omnicell : Investor Presentation – October 2025	PU

22-07-15	USA-Les valeurs à suivre à Wall Street (actualisé)
21-01-05	Omnicell : kooperiert im Rahmen der Ausweitung der Omnicell-Systeme im gesamten South East London NHS Integrated Care System mit dem Guy's and St Thomas' NHS Foundation Trust, London, bei der Entwicklung eines europäischen, technologiegestützten...
21-01-05	Omnicell : s’associe au Guy’s and St Thomas’ NHS Foundation Trust de Londres pour le développement d’un centre européen de veille technologique, dans le cadre de l’expansion des systèmes d’Omnicell dans l’ensemble du South East London NHS Integrated...
21-01-04	Quels ETF choisir pour investir dans les valeurs moyennes ?
20-12-09	USA-Les valeurs à suivre à Wall Street (actualisé)

1 day	+0.15%
1 week	+13.55%
Current month	+19.61%
1 month	+18.64%
3 months	+33.26%
6 months	+37.85%
Current year	-1.91%

1 week	38.32	45.36
1 month	33.25	45.36
Current year	22.66	47.69
1 year	22.66	47.7
3 years	22.66	77.14
5 years	22.66	187.28
10 years	22.66	187.28

Manager	Title	Age	Since
Randall Lipps CEO	Chief Executive Officer	67	2002-09-30
Harlan Radford DFI	Director of Finance/CFO	55	2025-09-14
Nnamdi Njoku COO	Chief Operating Officer	49	2024-10-06

Director	Title	Age	Since
Randall Lipps CHM	Chairman	67	1992-08-31
Mark Parrish BRD	Director/Board Member	69	2012-12-31
Joanne Bauer BRD	Director/Board Member	69	2013-12-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
OMNICELL, INC.	+0.37%	+13.55%	-7.28%	-8.14%	1.95B
VEEVA SYSTEMS INC.	-2.83%	-3.16%	-5.47%	+35.06%	39.3B
PRO MEDICUS LIMITED	+0.36%	-5.58%	-7.67%	+323.38%	17.06B
SECTRA AB	+0.88%	-0.22%	-2.78%	+56.14%	5.61B
HEARTFLOW, INC.	-2.63%	-7.19%	-	-	2.38B
XUNFEI HEALTHCARE TECHNOLOGY CO., LTD.	+0.41%	+4.88%	-	-	1.33B
B-SOFT CO.,LTD.	-1.37%	-3.08%	-11.11%	-41.73%	1.12B
RAYSEARCH LABORATORIES AB	-0.22%	-1.10%	+10.32%	+266.23%	819M
VERADIGM INC.	0.00%	+4.21%	-53.95%	-73.30%	841M
LUNIT INC.	-1.06%	-3.35%	-41.68%	+186.81%	755M
Average	-0.63%	+0.81%	-14.95%	+93.06%	7.12B
Weighted average by Cap.	-1.53%	-1.54%	-6.76%	+110.38%

	2025 *	2026 *
Net sales	1.18B 1.02B 954M 889M 1.64B 106B 1.78B 11.07B 4.3B 50.42B 4.44B 4.35B 186B	1.23B 1.06B 993M 925M 1.7B 111B 1.85B 11.51B 4.47B 52.44B 4.62B 4.52B 193B
Net income	13.68M 11.76M 11.03M 10.28M 18.93M 1.23B 20.57M 128M 49.72M 583M 51.35M 50.26M 2.15B	28.45M 24.44M 22.93M 21.37M 39.35M 2.56B 42.76M 266M 103M 1.21B 107M 104M 4.46B
Net Debt	-	-